




TM

## India Healthcare

15 April 2025

## 4QFY25 RESULT PREVIEW

## BSE Healthcare v/s BSE Sensex



Source: Bloomberg, Systematix Institutional Research

## Sector recommendations

Ticker	Mkt Cap (Rs bn)	TP (Rs)	Rating
SUNP	4,049	2,206	BUY
DIVI	1,484	4,118	SELL
CIPLA	1,182	1,705	BUY
DRRD	924	1,060	HOLD
ZYDUSLIF	874	1,011	SELL
LPC	899	2,126	HOLD
MANKIND	970	2,492	HOLD
AJP	320	3,460	HOLD
PLM	217	2,186	HOLD
INDR	21	325	HOLD
PFIZ	187	6,375	BUY
ORCP	37	1,843	BUY
SASV	8	457	BUY
JUBLPHAR	145	1,235	BUY
KRSNAA	24	1,071	BUY
SLPA	63	857	BUY

Source: Systematix Institutional Research

## Vishal Manchanda

vishalmanchanda@systematixgroup.in  
+91 9737437148

## Rushank Mody

rushankmody@systematixgroup.in  
+91 22 6704 8046

## Vamsi Hota

vamsihota@systematixgroup.in  
+91 22 6704 8099

## Low double-digit revenue growth likely

We expect stocks within our pharmaceutical universe to report low double-digit YoY revenue growth (~10%) during 4QFY25. Seasonal weakness in the domestic business could cause a QoQ slow down. We expect select companies in the US to benefit from the ramp up in generic Revlimid [Zyudus Life (ZYDUSLIF IN) and Sun Pharmaceuticals (SUNP IN)]. While Cipla (CIPLA IN) may benefit from a revival in generic lanreotide sales (supply issues getting sorted), Lupin (LPC IN) may see a gain in its US portfolio from seasonality (flu and antibiotics). The domestic branded formulation segment should expand in high single digits YoY. Dr. Reddy's (DRRD IN; led by inorganic initiatives), SUNP, Mankind (MANKIND IN; led by inorganic initiatives) and Ajanta Pharma (AJP IN) may record faster growth than peers. Although there have been no large, meaningful launches in the US during the quarter, we believe ramp up in existing ones would continue to support growth in the US business during the quarter.

- SUNP – Domestic growth to sustain, while generic Revlimid to support US generics:** We expect the contribution from generic Revlimid to step up QoQ and support the company's US generics business during 4QFY25. On the domestic front, the company may outpace peers to record double-digit growth. From a 4Q earnings call perspective, we expect focus to be on potential growth in its specialty asset – Leqselvi, which is expected to be launched shortly. **We estimate -1%/-4%/5% QoQ and 13%/27%/15% YoY revenue/EBITDA/PAT for SUNP, respectively for the quarter.**
- Divi's Laboratories (DIVI IN) – CRAMS growth could potentially soften, led by upcoming patent expiry:** We see CRAMS (expand) growth softening in 4QFY25 due to the upcoming patent expiry of a drug that the company supplies to an innovator. The drug is potentially the single-largest product in DIVI's base Two key monitorables for the company include a) Timeline of commercial supply for GLP-1 intermediate in its CRAMS business, and b) ramp up in its contrast media portfolio. **We estimate revenue/EBITDA/PAT growth of -4%/3%/-4% QoQ and 5%/5%/5% YoY, respectively, for DIVI.**
- CIPLA – US could surprise on Lanreotide recovery and Revlimid ramp up:** Supply constraints in generic lanreotide slowed CIPLA's US business in 3QFY25, but we expect a recovery here in 4Q. Domestic business could expand in the high single digit-low-double digit range. Timelines for launch of generic Abraxane (recently approved by USFDA), status of generic Advair and potential opportunity from its 505 (b)(2) approval – Nilotinib – would be key focus areas in the quarterly earnings call. **We estimate -5%/-16%/-34% QoQ and 9%/27%/11% YoY growth in revenue/EBITDA/PAT for CIPLA, respectively, during 4QFY25.**
- DRRD – US could revive post weakness in 3Q:** Ramp up in generic Revlimid could revive DRRD's US business in 4Q, post weakness in the 3QFY25. We expect the domestic business to clock in growth in high teens, led by various inorganic initiatives during the year (inlicensing of Sanofi Healthcare vaccine portfolio). Cost rationalization, GLP-1 opportunity, Rituximab biosimilar and high value launches in the US would be key focus areas during the quarterly earnings call.

We expect 3%/13%/18% QoQ and 22%/39%/26% YoY growth in revenue/EBITDA/PAT for DRRD, respectively, during 4Q.

5. **ZYDUSLIF – Sharp sequential growth in the US geography and consumer segment:** This could be an extraordinary quarter for ZYDUSLIF, led by sharp QoQ growth in the US, supported by favorable seasonality in the consumer business. The domestic business though could be lackluster. Likely discussion areas in the earnings call: a) follow up on high-value launches in the US, b) timelines around clinical data on Saroglitazar in primary biliary cholangitis, and c) recent acquisition in the medical device space. **We estimate 24%/69%/52% QoQ and 18%/44%/31% YoY growth in ZYDUSLIF's revenue/EBITDA/PAT, respectively, during 4QFY25.**
6. **LPC - Numbers could be sequentially flattish:** US could record mid single-digit growth, led by seasonality and ramp up in high-value products. India business may report high single-digit growth. Tolvaptan launch in the US could be the key discussion area during the earning call, in our view. **We estimate -4%/-6%/-10% QoQ and 12%/29%/115% YoY growth in LPC's revenue/EBITDA/PAT, respectively, during 4QFY25.**
7. **MANKIND – Exports may weaken QoQ:** MANKIND could post strong high-teen growth in the domestic branded prescription formulation business, led by BSV acquisition, which was closed in 3QFY25. We expect the growth revival in its consumer business during 3Q to sustain in 4Q. However, exports may weaken QoQ. Growth acceleration in the domestic branded formulations business and margin expansion would be key focus during the quarterly earnings call, we believe. **We estimate -3%/-2%/-7% QoQ and 29%/37%/-25% YoY growth in MANKIND's revenue/EBITDA/PAT, respectively.**
8. **AJP – Branded markets to grow in double digits, Institutional business may be impacted:** AJP may see double-digit YoY growth in its branded markets, led by the expansion in its field force and foray into new therapies. The US business may report flat growth QoQ, given the absence of new launches. Key points that could be discussed during the quarterly earnings call are a) impact on its institutional business owing to the cut in funding, b) expected growth in the US markets in FY26, and c) progress in the branded markets. **We estimate -2%/-7%/-7% QoQ and 6%/7%/7% YoY growth in AJP's revenue/EBITDA/PAT, respectively, during 4QFY25.**
9. **Poly Medicare (PLM IN) – Domestic growth slated to strengthen:** New launches in the domestic markets and expansion in sales force should strengthen PLM's 4QFY25 growth, with the export business expected to retain momentum. **We estimate 11%/11%/10% QoQ and 24%/31%/38% YoY growth in PLM's revenue/EBITDA/PAT, respectively, during 4QFY25.**
10. **Indoco Remedies (INDR IN) – Weakness in the US and elevated expenses persist:** Although INDR's domestic business growth was strong in 3Q, we expect a slowdown in 4Q. We expect the US business to stay weak, as recovery would be contingent on supplies resuming and the company completing the remediation at its sterile facility. The Europe business could improve QoQ, given the company's collaboration with Clarity Pharma for the UK markets. Growing debt, USFDA's reinspection of the sterile facility and acceleration of growth in the domestic / EU markets would be key focus areas of discussion in the quarterly earnings call. **We estimate -9%/-43%/18% QoQ and -17%/-86%/-252% YoY growth in INDR's revenue/EBITDA/PAT respectively, for 4QFY25.**

- 11. Pfizer (PFIZ IN) – Expect growth to rebound:** Led by its specialty portfolio – Prevenar, Eliquis and core brands – Becosule, we expect PFIZ's growth to revive to high single-digit to mid teens during 4Q. **We estimate 15%/38%/30% QoQ and 13%/6%/-7% YoY growth in PFIZ's revenue/EBITDA/PAT, respectively, during 4QFY25.**
- 12. Orchid Pharma (ORCP IN) – 4Q may see volume-led growth:** We believe ORCP would continue to leverage its recently implemented capacities to deliver committed volume growth. However, recent pricing pressures could offset a large part of the same. Pricing improvement, potential new high-value approvals, status of ongoing backward integration project would be the key discussion areas during the earnings call. **We estimate 5%/6%/6% QoQ and 5%/-3%/-33% YoY growth in ORCP's revenue/EBITDA/PAT, respectively, during 4QFY25.**
- 13. Sasta Sundar Ventures (SASV IN) – Retailer Shakti growth momentum to help offset the pain of decline in Flipkart Health:** SASV's Retailer Shakti business will likely continue its strong growth momentum, accentuated by the newly added online business. However, upfront expenses to scale up the online retail pharmacy could dent margins. **We estimate 7%/-8%/-50% QoQ and -1%/55%/-181% YoY growth in SASV's revenue/EBITDA/PAT, respectively, during 4QFY25.**
- 14. Jubilant Pharmova (JUBLPHAR IN) – Momentum in CRDS and rebound in generic and allergy immunotherapy to shape 4Q performance**
- We expect growth in JUBLPHAR's CRDS business to continue during the year, given that it has onboarded large innovator clients. The generic business continues to be in the turnaround phase and we could see favorable progress in this space. The allergy immunotherapy business could rebound post some weakness in 3QFY25. While the radiopharma and radiopharmacy(?) businesses should deliver high single digit and double-digit growth, respectively, margin contribution will need to be monitored. **We estimate 5%/15%/34% QoQ and 9%/22%/-318% YoY growth in JUBLPHAR's revenue/EBITDA/PAT, respectively, during 4QFY25.**
- 15. Krsnaa Diagnostics (KRSNAA IN) –New center addition to drive growth:** We expect KRSNAA to deliver high teens growth during the quarter, which would be led by ramp up in operations at its recently opened centers and addition of new centers. Progress around the B2C initiative and award of new tenders would be key areas of discussion during the quarterly conference call, in our view. **We estimate 11%/16%/7% QoQ and 17%/20%/11% YoY growth in KRSNAA's revenue/EBITDA/PAT, respectively, during 4QFY25.**
- 16. Shilpa Medicare (SLPA IN) – New launches and capacity expansion in the API business to shape growth:** Ramp up in generic Nilotinib in the EU market as a sole / first generic and ramp up of 505 (B) (2) launches in the US would shape 4QFY25, in our view. We assume flattish contribution from licensing income, given the uncertainty here. Execution around 505 (B) (2) launches in the US and timelines around new opportunities (transdermal patch, Aflibercept biosimilar, Oxylanthanum carbonate, Nor UDCA, other CDMO opportunities) would be key focus areas during the earnings call. **We estimate SLPA's revenue/EBITDA/PAT to grow at 23%/67%/85% QoQ and 35%/93%/136% YoY, respectively, during 4QFY25.**

## Exhibit 1: 4QFY25E result estimates

Company	4QFY25E				Change in revenue		Change in EBITDA		Change in PAT	
	Revenue	EBITDA	PAT	EPS	YoY	QoQ	YoY	QoQ	YoY	QoQ
	(Rs mn)	(Rs mn)	(Rs mn)	(Rs)	(%)	(%)	(%)	(%)	(%)	(%)
SUNP	133,387	38,622	30,483	12.7	12.9	-0.7	27.2	-3.7	14.8	5.0
DIVI	24,182	7,645	5,646	21.3	5.0	4.3	4.6	2.9	4.9	-4.1
CIPLA	67,437	16,769	10,382	12.9	9.4	-4.7	27.4	-15.7	10.6	-33.9
DRRD	86,387	26,070	16,533	19.8	22.0	3.4	39.3	13.4	26.5	17.8
ZYDUSLIF	65,087	23,497	15,538	15.4	17.6	23.5	44.1	69.3	31.4	51.8
LPC	55,687	12,823	7,716	16.9	12.3	-3.5	28.6	-6.1	114.7	-9.8
MANKIND	31,366	8,119	3,547	8.9	28.5	-2.9	37.4	-2.2	-24.7	-6.7
AJP	11,214	2,988	2,169	17.4	6.4	-2.2	7.4	-6.9	7.0	-6.9
PLM	4,688	1,267	941	9.3	24.0	10.5	31.2	10.6	37.6	10.4
INDR	3,722	69	-335	-3.6	-17.2	-9.3	-85.9	-42.5	-252.1	18.0
PFIZ	6,194	2,010	1,663	36.3	13.3	15.1	6.1	37.7	-7.0	30.3
ORCP	2,280	280	221	4.4	5.0	4.9	-3.1	6.3	-32.9	6.4
SASV	3,000	-231	-134	-4.2	-0.8	7.2	55.2	-8.4	-181.2	-50.4
JUBLPHAR	19,164	3,305	1,349	8.5	9.0	5.2	21.8	15.0	-318.3	34.0
KRSNAA	1,937	523	208	6.4	16.5	11.0	19.7	16.0	10.9	6.9
SLPA	3,932	1,349	582	5.9	34.8	23.1	92.6	67.2	136.2	85.1

Source: Company, Systematix Institutional Research

## Exhibit 2: 4QFY25E US and domestic sales growth

Company	Segment	YoY	QoQ
Sun Pharma	Domestic	10%	-5%
	US sales	13%	12%
Cipla	Domestic	10%	-16%
	US sales	10%	8%
Dr. Reddy's	Domestic	20%	0%
	US sales	23%	18%
Zydus Life	Domestic	5%	-3%
	US sales	29%	35%
Lupin	Domestic	8%	-11%
	US sales	16%	4%
Mankind	Domestic	20%	-6%
Ajanta Pharma	Domestic	10%	4%
	US sales	4%	3%
Indoco Remedies	Domestic	4%	-18%
	US sales	-40%	0%
Pfizer	Domestic	13%	15%

Source: Company, Systematix Institutional Research

## Exhibit 3: Valuation snapshot

Company	Rating	CMP	Target Price	Upside (%)	Mkt.Cap (Rs bn)	CAGR over FY25E-27E (%)			Valuation on FY27E	
						Revenue	EBITDA	EPS	PE (x)	EV/EBITDA (x)
SUNP	BUY	1,708	2,206	29.2%	4,049	8.2	7.5	12.9	27.2	20.8
DIVI	SELL	5,675	4,118	-27.4%	1,484	12.2	14.7	14.8	54.8	37.8
CIPLA	BUY	1,465	1,705	16.4%	1,182	5.7	0.6	3.9	21.5	14.8
DRRD	HOLD	1,143	1,060	-7.2%	924	-0.3	-29.1	-32.7	36.4	17.6
ZYDUSLIF	SELL	873	1,011	15.9%	874	-0.3	-11.0	-6.5	20.5	12.9
LPC	HOLD	2,002	2,126	6.2%	899	8.8	8.4	7.4	23.9	13.8
MANKIND	HOLD	2,405	2,492	3.6%	970	18.3	22.3	23.3	34.0	20.3
AJP	HOLD	2,619	3,460	32.1%	320	12.1	15.6	16.0	28.5	19.2
PLM	HOLD	2,212	2,186	-1.2%	217	23.0	29.7	20.0	45.7	28.1
INDR	HOLD	234	325	39.0%	21	14.0	61.7	NA	29.4	9.7
PFIZ	BUY	4,110	6,375	55.1%	187	14.5	16.8	18.9	22.1	15.1
ORCP	BUY	751	1,843	145.5%	37	62.0	105.3	51.7	16.6	8.4
SASV	BUY	264	457	73.0%	8	39.4	NA	-48.8	-28.6	187.5
JUBLPHAR	BUY	919	1,235	34.4%	145	9.7	18.6	-1.9	18.5	9.6
KRSNAA	BUY	785	1,071	36.5%	24	30.4	31.0	39.0	16.8	7.4
SLPA	BUY	647	857	32.5%	63	15.7	31.5	65.9	18.9	9.6

Source: Company, Systematix Institutional Research

**DISCLOSURES/APPENDIX****I. ANALYST CERTIFICATION**

I, **Vishal Manchanda, Rushank Mody, Vamsi Hota**; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

I. **ISSUER SPECIFIC REGULATORY DISCLOSURES**, unless specifically mentioned in point no. 9 below:

- The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
- The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
- The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
- The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
- SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
- The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
- The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
- Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

- There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

**STOCK RATINGS**

**BUY (B):** The stock's total return is expected to exceed 15% over the next 12 months.

**HOLD (H):** The stock's total return is expected to be within -15% to +15% over the next 12 months.

**SELL (S):** The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

**NOT RATED (NR):** The analyst has no recommendation on the stock under review.

**INDUSTRY VIEWS**

**ATTRACTIVE (AT):** Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

**NEUTRAL (NL):** Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

**CAUTIOUS (CS):** Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

**II. DISCLAIMER**

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication, redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link,

is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

**SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.**

**Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.**



#### Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell : grievance@systematixgroup.in

Details of Registration : CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI : ARN - 64917